SCHEDULE 13G/A: TCG Crossover Entities Fully Divest Stake in AN2 Therapeutics

TCG Crossover GP I, LLC, TCG Crossover Fund I, L.P., and Chen Yu have reported a complete divestment of their beneficial ownership in AN2 Therapeutics, Inc., reducing their stake to 0% as of December 31, 2024.

Summary

• This document is Amendment No. 3 to the Schedule 13G filing for AN2 Therapeutics, Inc. (CUSIP: 037326105).
• The reporting persons are TCG Crossover GP I, LLC, TCG Crossover Fund I, L.P., and Chen Yu, all based out of 705 High St., Palo Alto, CA 94301.
• As of December 31, 2024, the aggregate amount of common stock beneficially owned by these reporting persons is 0.00 shares, representing 0% of the class.
• This filing indicates a complete divestment of their previous holdings in AN2 Therapeutics, Inc.
• The original Schedule 13G was filed on July 25, 2023, with subsequent amendments on February 9, 2024 (Amendment No. 1) and November 13, 2024 (Amendment No. 2).

Sentiment

Score: 3

Explanation: The complete divestment of shares by institutional investors is generally perceived as a negative signal, indicating a potential loss of confidence or a strategic exit from the investment.

Negatives

• The complete divestment of shares by TCG Crossover GP I, LLC, TCG Crossover Fund I, L.P., and Chen Yu, reducing their beneficial ownership to 0%, could be perceived negatively by the market, potentially signaling a lack of confidence or a strategic portfolio reallocation away from AN2 Therapeutics, Inc.

Risks

• The complete divestment by institutional investors may lead to negative market sentiment and potential downward pressure on AN2 Therapeutics, Inc.'s share price.

Future Outlook

This filing is an ownership disclosure and does not contain any forward-looking statements or guidance from AN2 Therapeutics, Inc. regarding its future outlook.

Industry Context

This filing reflects a significant portfolio decision by TCG Crossover entities to fully exit their position in AN2 Therapeutics, Inc. While the specific reasons are not disclosed, such a complete divestment by an institutional investor could be interpreted by the market as a signal regarding the company's prospects or a broader strategic shift within the investor's portfolio, potentially impacting market perception within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The complete divestment by institutional investors may lead to negative market sentiment and potential downward pressure on the share price due to perceived loss of institutional confidence.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, TCG Crossover, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, SEC Filing, Institutional Investor, Ownership Change